Distribution service company Chindex International of Bethesda, MD, this month finalized an agreement with China's Ministry of Public Health for the purchase of $14 million of medical equipment. Initiated in July, the agreement resulted from a
Distribution service company Chindex International of Bethesda, MD, this month finalized an agreement with China's Ministry of Public Health for the purchase of $14 million of medical equipment. Initiated in July, the agreement resulted from a partnership between China's Ministry of Health Foreign Loan Office, the U.S. Department of Commerce, the U.S. Export-Import Bank, and China's Ministry of Foreign Trade and Economic Cooperation and State Planning Commission (SCAN 7/22/98).
The deal was financed through a loan to the Bank of China in Beijing from ABN AMRO Bank of the Netherlands, and the loan was guaranteed by the U.S. Export-Import Bank. The transaction represents Chindex's second loan project for U.S. medical equipment.
Vendors included in the agreement are Acuson, Lunar, Steris, Johnson & Johnson Ortho Clinical Diagnostics, Trex Medical/XRE Division, and Nova Biomedical. Shipments of the equipment began in late 1998, and will continue through the first quarter of 1999.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.